



INDEX

Chapter No.	Contents	Page No.
1	Introduction	1
1.1	Introduction.....	1
1.2	Objectives of the work.....	4
1.3	Materials.....	5
2	Literature Review	6
2.1	Cancer	6
2.1.1	What is Cancer?	6
2.1.2	Growth of solid tumors	6
2.1.3	Cancer Therapy	8
2.2	Tumor Angiogenesis	13
2.2.1	Angiogenesis	13
2.2.2	History: Angiogenesis	14
2.2.3	Tumour growth is angiogenesis dependant	15
2.2.4	Angiogenic Switch	15
2.2.5	The Process of Angiogenesis	17
2.2.6	Tumour angiogenesis: molecular mechanism	19
2.2.7	Angiogenesis regulators: Endogenous factors	21
2.2.8	Tumour Vasculature: Morphology and characteristics	25
2.2.9	Enhanced Permeation and Retention effect (EPR)	26
2.3	Antiangiogenic Therapy	31
2.3.1	Antiangiogenesis : History	31
2.3.2	Antiangiogenic Therapy	32
2.3.3	Antiangiogenesis strategies	33
2.3.4	Different classifications for Angiogenesis Inhibitors (AIs) .	34
2.3.5	Combination therapy	35
2.3.6	Normalization of Tumor Vasculature	37
2.3.7	Criteria for Antiangiogenic Activity	39
2.3.8	Natural Antiangiogenic Agents	39

Chapter No.	Contents	Page No.
2.4	Nanotechnology in cancer	46
2.4.1	Introduction: Cancer Nanotechnology	46
2.4.2	Polymeric Nanoparticles	47
2.4.3	Clearance mechanism and circulation time	48
2.4.4	Mechanisms of targeting: Passive and Active	49
2.4.5	Polymeric Nanoparticles	52
2.4.6	Preparation methods	55
2.4.7	Characterisation of nanoparticles	61
2.5	<i>In Vitro</i> Studies on Nanoparticles	70
2.5.1	<i>In vitro</i> release study	70
2.5.2	<i>In vitro</i> cell line studies	71
2.6	Plan of work	76
3	Drug Profiles	78
3.1	Etoposide	78
3.2	Quercetin Dihydrate	83
4	Analytical methods for drug estimation	92
4.1	Solubility studies	92
4.2	Estimation of Etoposide and Quercetin Dihydrate in PLGA nanoparticles	92
4.3	Estimation of Etoposide and Quercetin Dihydrate in pH 7.4 phosphate buffer	98
4.4	Result and discussion	105
5	Preparation and Characterisation of nanoparticles	111
5.1	Introduction	111
5.2	Preparation of PLGA nanoparticles	111
5.3	Optimization of Nanoparticle Formulations	112
5.4	Characterization of nanoparticle formulations	120
5.5	Stability studies	125

Chapter No.	Contents	Page No.
5.6	Results and discussion	127
5.7	Conclusion.....	131
6	<i>In-Vitro</i> studies on nanoparticles	133
6.1	Introduction	133
6.2	In vitro drug release from ETN and QDN.....	133
6.3	In vitro cell line studies: Cytotoxicity by MTT assay.....	133
6.4	Result and Discussion.....	135
6.5	Conclusions	142
7	<i>In-Vivo</i> studies on nanoparticles	144
7.1	Introduction	144
7.2	Radiolabeling	145
7.3	Tumor growth inhibitory activity	154
7.4	Histopathological studies:Tumor microvessel density evaluation	154
7.5	Results and Discussion	163
7.6	Conclusions	166
8	Summary and Conclusions	170